FluoroPharma Medical, based in Montclair, N.J., announced yesterday that new results from an ongoing phase II clinical trial for F-18 FCPHA cardiac PET for the diagnosis of acute coronary artery disease (CAD) were positive and providing validation for further research. {read more here}